PXLW Pixelworks, Inc. gains 65% Sep 3, 2021

Pixelworks, Inc. develops and markets semiconductor and software solutions. The company provides video display processor products, including image processor ICs, such as embedded microprocessors, digital signal processing technology, and software that control the operations and signal processing within high-end display systems; and video co-processor ICs that work with an image processor to post-process video signals to enhance the performance or feature set of the overall video solution, as well as transcoder ICs, such as embedded microprocessors, digital signal processing technology, and software that control the operations and signal processing for converting bitrates, resolutions, and codecs. As of December 31, 2019, it had an intellectual property portfolio of 347 patents related to the visual display of digital image data. The company's products are used in smartphones, tablets, and projectors. Pixelworks, Inc. sells its products through a direct sales force, as well as distributors and manufacturers' representatives worldwide. The company was founded in 1997 and is headquartered in San Jose, California.http://www.priceseries.com/trade/PXLW-Pixelworks-Inc-stock-gains-65-percent-a-Trade-Record-by-priceSeries-2021081920210903.html

NVUS Novus Therapeutics, Inc. gains 19% Sep 3, 2021

Tokai Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies for prostate cancer and other hormonally-driven diseases. Its lead drug candidate is galeterone, an oral small molecule that is in various clinical trials for the treatment of patients with metastatic castration-resistant prostate cancer. The company's androgen receptor degradation agents drug discovery program is focused on identifying and developing compounds for patients with androgen receptor signaling diseases, including prostate cancer. Tokai Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Boston, Massachusetts.http://www.priceseries.com/trade/NVUS-Novus-Therapeutics-Inc-stock-gains-19-percent-a-Trade-Record-by-priceSeries-2021082020210903.html

CNFR Conifer Holdings, Inc. gains 19% Sep 3, 2021

Conifer Holdings, Inc., an insurance holding company, offers insurance coverage in specialty commercial and specialty personal product lines. It underwrites various specialty insurance products, including property, general liability, commercial multi-peril, liquor liability, and automobile policies. The company serves the commercial insurance needs of owner-operated businesses in the markets, such as hospitality, which include restaurants, bars, taverns, and bowling centers, as well as small grocery and convenience stores; artisan contractors comprising plumbers, painters, carpenters, electricians, and other independent contractors; and security service providers, such as companies that provide security guard services, security alarm products and services, and private investigative services. It also offers specialty homeowners' insurance products, including dwelling insurance tailored for owners of lower valued homes in Illinois, Indiana, Louisiana, and Texas; and wind-exposed catastrophe coverage, such as hurricane and wind coverage to under-served homeowners in Hawaii, Texas, and Florida. The company markets and sells its insurance products through a network of approximately 6,300 independent agents, such as general agents in 50 states in the United States. Conifer Holdings, Inc. was founded in 2009 and is headquartered in Birmingham, Michigan with additional office facilities in Florida, Texas, Pennsylvania, and Tennessee.http://www.priceseries.com/trade/CNFR-Conifer-Holdings-Inc-stock-gains-19-percent-a-Trade-Record-by-priceSeries-2021082020210903.html

CLSD Clearside Biomedical Inc gains 17% Sep 3, 2021

Clearside Biomedical, Inc., a biopharmaceutical company, develops and delivers treatment that restore and preserve vision for people with serious eye diseases. Its preclinical products include CLS-AX, an axitinib for suprachoroidal injection. It also develops XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of macular edema associated with uveitis, diabetic macular edema, and macular edema associated with retinal vein occlusion. The company was founded in 2011 and is headquartered in Alpharetta, Georgia.http://www.priceseries.com/trade/CLSD-Clearside-Biomedical-Inc-stock-gains-17-percent-a-Trade-Record-by-priceSeries-2021082020210903.html

BYSI BeyondSpring Inc. gains 18% Sep 3, 2021

BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development and commercialization of immuno-oncology cancer therapies. The company's lead asset is the Plinabulin that is in late stage clinical trials as an anti-cancer agent in combination with docetaxel in advanced non-small cell lung cancer (NSCLC) for the prevention of high and intermediate risk chemotherapy-induced neutropenia. It is also developing Plinabulin in combination with various immuno-oncology agents, including nivolumab, a programmed cell death protein 1 antibody for the treatment of NSCLC; nivolumab and ipilimumab, a CTLA-4 antibody to treat small cell lung cancer; and death protein 1 or programmed death-ligand 1, an antibodies and radiation or chemotherapy for the treatment of multiple cancers. In addition, the company engages in the development of three small molecule immune agents in preclinical stages; and a drug development platform using ubiquitin mediated protein degradation pathway. BeyondSpring Inc. has collaboration agreements with the Fred Hutchinson Cancer Research Center and the University of Washington. The company was founded in 2010 and is headquartered in New York, New York.http://www.priceseries.com/trade/BYSI-BeyondSpring-Inc-stock-gains-18-percent-a-Trade-Record-by-priceSeries-2021082320210903.html

XTLB XTL Biopharmaceuticals Ltd. gains 18% Sep 3, 2021

XTL Biopharmaceuticals Ltd., a biopharmaceutical company, is engaged in the acquisition and development of pharmaceutical products for the treatment of unmet medical needs. The company's lead drug candidate is hCDR1, a Phase II clinical trial product for the treatment of systemic lupus erythematosus related autoimmune process; and recombinant human erythropoietin (rHuEPO) for the treatment of multiple myeloma patients, as well as for the treatment of various anemias, including anemia of kidney disease and cancer-related anemia. Its rHuEPO has also granted an orphan drug designation from the FDA for the treatment of multiple myeloma. The company is also developing SAM-101, a proprietary combination of antipsychotic drugs and a medicinal compound, which has completed Phase IIa clinical trials as a therapy for psychotic diseases with focus on schizophrenia. It has a licensing agreement with Yeda Research and Development Company for the development of hCDR1. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was founded in 1993 and is based in Herzliya, Israel.http://www.priceseries.com/trade/XTLB-XTL-Biopharmaceuticals-Ltd-stock-gains-18-percent-a-Trade-Record-by-priceSeries-2021081920210903.html

PXLW Pixelworks, Inc. gains 65% Sep 3, 2021

Pixelworks, Inc. develops and markets semiconductor and software solutions. The company provides video display processor products, including image processor ICs, such as embedded microprocessors, digital signal processing technology, and software that control the operations and signal processing within high-end display systems; and video co-processor ICs that work with an image processor to post-process video signals to enhance the performance or feature set of the overall video solution, as well as transcoder ICs, such as embedded microprocessors, digital signal processing technology, and software that control the operations and signal processing for converting bitrates, resolutions, and codecs. As of December 31, 2019, it had an intellectual property portfolio of 347 patents related to the visual display of digital image data. The company's products are used in smartphones, tablets, and projectors. Pixelworks, Inc. sells its products through a direct sales force, as well as distributors and manufacturers' representatives worldwide. The company was founded in 1997 and is headquartered in San Jose, California.http://www.priceseries.com/trade/PXLW-Pixelworks-Inc-stock-gains-65-percent-a-Trade-Record-by-priceSeries-2021081920210903.html

CNFR Conifer Holdings, Inc. gains 19% Sep 3, 2021

Conifer Holdings, Inc., an insurance holding company, offers insurance coverage in specialty commercial and specialty personal product lines. It underwrites various specialty insurance products, including property, general liability, commercial multi-peril, liquor liability, and automobile policies. The company serves the commercial insurance needs of owner-operated businesses in the markets, such as hospitality, which include restaurants, bars, taverns, and bowling centers, as well as small grocery and convenience stores; artisan contractors comprising plumbers, painters, carpenters, electricians, and other independent contractors; and security service providers, such as companies that provide security guard services, security alarm products and services, and private investigative services. It also offers specialty homeowners' insurance products, including dwelling insurance tailored for owners of lower valued homes in Illinois, Indiana, Louisiana, and Texas; and wind-exposed catastrophe coverage, such as hurricane and wind coverage to under-served homeowners in Hawaii, Texas, and Florida. The company markets and sells its insurance products through a network of approximately 6,300 independent agents, such as general agents in 50 states in the United States. Conifer Holdings, Inc. was founded in 2009 and is headquartered in Birmingham, Michigan with additional office facilities in Florida, Texas, Pennsylvania, and Tennessee.http://www.priceseries.com/trade/CNFR-Conifer-Holdings-Inc-stock-gains-19-percent-a-Trade-Record-by-priceSeries-2021082020210903.html

CLSD Clearside Biomedical Inc gains 17% Sep 3, 2021

Clearside Biomedical, Inc., a biopharmaceutical company, develops and delivers treatment that restore and preserve vision for people with serious eye diseases. Its preclinical products include CLS-AX, an axitinib for suprachoroidal injection. It also develops XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of macular edema associated with uveitis, diabetic macular edema, and macular edema associated with retinal vein occlusion. The company was founded in 2011 and is headquartered in Alpharetta, Georgia.http://www.priceseries.com/trade/CLSD-Clearside-Biomedical-Inc-stock-gains-17-percent-a-Trade-Record-by-priceSeries-2021082020210903.html

BYSI BeyondSpring Inc. gains 18% Sep 3, 2021

BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development and commercialization of immuno-oncology cancer therapies. The company's lead asset is the Plinabulin that is in late stage clinical trials as an anti-cancer agent in combination with docetaxel in advanced non-small cell lung cancer (NSCLC) for the prevention of high and intermediate risk chemotherapy-induced neutropenia. It is also developing Plinabulin in combination with various immuno-oncology agents, including nivolumab, a programmed cell death protein 1 antibody for the treatment of NSCLC; nivolumab and ipilimumab, a CTLA-4 antibody to treat small cell lung cancer; and death protein 1 or programmed death-ligand 1, an antibodies and radiation or chemotherapy for the treatment of multiple cancers. In addition, the company engages in the development of three small molecule immune agents in preclinical stages; and a drug development platform using ubiquitin mediated protein degradation pathway. BeyondSpring Inc. has collaboration agreements with the Fred Hutchinson Cancer Research Center and the University of Washington. The company was founded in 2010 and is headquartered in New York, New York.http://www.priceseries.com/trade/BYSI-BeyondSpring-Inc-stock-gains-18-percent-a-Trade-Record-by-priceSeries-2021082320210903.html